MedTrace Logo

Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation

NCT02955264 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-01-08

No results posted yet for this study

Summary

The goal of this study is to better characterize the metabolic alterations and sugar structure alterations (glycosylation abnormalities) in patients diagnosed with Congenital Disorders of Glycosylation. The investigators aim to assess the safety and tolerability of oral galactose treatment in a small pilot group of Congenital Disorders of Glycosylation patients. The investigators will also determine the relationship between simple milk sugar intake (galactose dose) in the diet and the blood and urine markers of protein glycosylation abnormalities.

Conditions

  • Congenital Disorders of Glycosylation

Interventions

DIETARY_SUPPLEMENT

D-Galactose

D-Galactose is an oral powdered dietary supplement to be taken by mouth.

Sponsors & Collaborators

  • Tulane University

    lead OTHER

Principal Investigators

  • Eva Morava-Kozicz, MD, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-11-30
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02955264 on ClinicalTrials.gov